Showing results (21-30 of 47) with videos related to
Sort By:
Pageof 5
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|June 21, 2002
Multidimensional scaling as a tool for analysing quality of life dataG Kemmler, B Holzner, M Kopp, et al.Fortschritte Der Neurologie-Psychiatrie|September 1, 1991
[Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind study]W W Fleischhacker, C Barnas, C H Stuppäck, et al.International Clinical Psychopharmacology|January 1, 1992
Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidolC Barnas, C H Stuppäck, C Miller, et al.Fortschritte Der Neurologie-Psychiatrie|September 1, 1991
[Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol]C Barnas, C H Stuppäck, C Miller, et al.Journal of Clinical Epidemiology|July 21, 2009
A new approach to combining clinical relevance and statistical significance for evaluation of quality of life changes in the individual patientG Kemmler, A Zabernigg, K Gattringer, et al.Psychiatry Research|May 1, 1992
Neopterin production in acute schizophrenic patients: an indicator of alterations of cell-mediated immunityB Sperner-Unterweger, C Barnas, D Fuchs, et al.Schizophrenia Research|July 1, 1989
Is schizophrenia linked to alteration in cellular immunity?B Sperner-Unterweger, C Barnas, W W Fleischhacker, et al.Schizophrenia Research|July 31, 1999
T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patientsB Sperner-Unterweger, A Whitworth, G Kemmler, et al.Current Drug Metabolism|September 11, 2008
Chronic immune stimulation correlates with reduced phenylalanine turnoverG Neurauter, K Schröcksnadel, S Scholl-Bürgi, et al.Psychopharmacology|March 1, 1996
Does eosinophilia predict clozapine induced neutropenia?M Hummer, B Sperner-Unterweger, G Kemmler, et al.Pageof 5